Reducing cardiovascular disease risk in type 2 diabetes: Is the focus on glycaemia warranted?

Diabetes, Obesity and Metabolism

Volumn 15, Issue 5, 2013, Pages 387-391

  Ferguson, L D ^a   Sattar, N ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular disease; Glycaemic control; Treatment guidelines; Type 2 diabetes

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MACROALBUMINURIA; META ANALYSIS (TOPIC); MICROALBUMINURIA; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; WEIGHT GAIN;

EID: 84876308987     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12018     Document Type: Review

References (24)

1. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
2. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
3. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405.
4. 1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012; 55: 636-643.
5. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycaemia. N Engl J Med 2012; 367: 319-328.
6. Ray K, Seshasai S, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
7. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
8. 1c and mortality: causation and confounding. Diabetologia 2012; 55: 2307-2311.
9. Greenfield S, Billimek J, Pellegrini F et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 2009; 151: 854-860.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
12. Holman RR, Paul SK, Bethel MA et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
13. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
14. The Action to Control Cardiovascular Risk In Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
15. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33: 1389-1394.
16. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298.
17. Hemmingsen B, Lund SS, Gluud C. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898.
18. Looker HC, Nyangoma SO, Cromie D et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia 2012; 55: 2335-2342.
19. Coca SG, Ismail-Beigi F, Haq N et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus. Arch Intern Med 2012; 172: 761-769.
20. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
21. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419.
22. Holman RR, Paul SK, Bethel MA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
23. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010; 53: 2079-2085.
24. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.